From Pills to Protocols: What GLP-1 Medicines Can And Cannot Do

GLP-1 medicines have changed the treatment of type 2 diabetes and obesity. They can also reduce cardiovascular risk in some high-risk groups. That does not make them anti-ageing drugs, a substitute for every other medicine, or a shortcut around clinical care.

The GLP-1 conversation is often forced into two unhelpful positions: miracle treatment or dangerous fad. The evidence supports neither. These medicines are effective prescription treatments for defined conditions, with benefits that can extend beyond the number on a weighing scale. They also have side effects, contraindications, monitoring needs, and a practical problem that receives less attention: what happens over the long term.

The practical question is not simply, ‘Do GLP-1 medicines work?’ It is: what is the treatment goal, who is the medicine for, what evidence applies to that person, and what support is needed before, during, and after treatment?

What Is Glucagon-Like Peptide-1 (GLP-1)?

Glucagon-like peptide-1, or GLP-1, is a hormone released from the gut after eating. It helps the pancreas release insulin when glucose is elevated, reduces glucagon secretion, slows gastric emptying, and contributes to fullness and appetite regulation (Holst, 2007). Natural GLP-1 is broken down within minutes. Medicines such as semaglutide and liraglutide are engineered to activate the same receptor for much longer (Lau et al., 2015).

‘GLP-1 medicine’ is a class description, not a single product. Different medicines have different approved uses, doses, delivery methods, and evidence. Tirzepatide, for example, activates both GIP and GLP-1 receptors. Brand names are not interchangeable, and a diabetes dose is not automatically a weight-management dose. Because GLP-1 receptors are involved in several tissues, researchers are studying effects across metabolic, cardiovascular, kidney, liver, and neurological health.

What The Evidence Shows

Weight And Glucose Regulation

The clearest evidence is in type 2 diabetes and weight management. In the STEP 1 randomised trial, adults with overweight or obesity but without diabetes received weekly semaglutide 2.4 mg or placebo alongside lifestyle support. At 68 weeks, mean weight loss was about 15% with semaglutide and about 2% with placebo, although individual responses varied and gastrointestinal side effects were common (Wilding et al., 2021).

This result does not mean that everyone seeking weight loss needs medication. Prescription decisions depend on the approved indication, body mass index, weight-related conditions, previous treatment, current medicines, contraindications, and the person’s goals. The medicine supports treatment; it does not replace clinical judgement.

Cardiovascular Outcomes

Some benefits are more consequential than weight loss. In SELECT, semaglutide reduced major cardiovascular events by 20% relative to placebo in adults aged 45 or older who had established cardiovascular disease and overweight or obesity, but not diabetes (Lincoff et al., 2023). This was a high-risk population with existing cardiovascular disease. The result should not be translated into a promise that GLP-1 medicines prevent heart disease in every user.

Cognition And Ageing

In two large trials involving people with early symptomatic Alzheimer’s disease, oral semaglutide did not slow clinical progression compared with placebo (Cummings et al., 2026). GLP-1 medicines should therefore not be described as neuroprotective, cognition-preserving, or longevity treatments. Research continues, but ‘being studied’ is not the same as ‘shown to work’.

Why Routine GLP-1 Testing Is Not A Useful Baseline

GLP-1 concentrations change rapidly after food, active and total GLP-1 are different measurements, and commercial assays can produce different absolute results from the same samples (Wewer Albrechtsen et al., 2014).

For most people, clinicians do not diagnose ‘low GLP-1’ or decide whether to prescribe a GLP-1 medicine from a GLP-1 blood level. They assess the condition being treated and the outcomes that matter, such as HbA1c, fasting glucose, weight history, waist circumference, blood pressure, lipid levels, liver or kidney measures, symptoms, and current medicines. A continuous glucose monitor can show glucose patterns. It does not measure GLP-1 activity and cannot confirm that someone’s GLP-1 system is ‘working optimally’.

Medication Review, Not Automatic Deprescribing

GLP-1 treatment can change glucose levels, appetite, food intake, and gastric emptying. That can affect how other medicines are used. The risk of hypoglycaemia is higher when semaglutide is combined with insulin or medicines that stimulate insulin release, and slower gastric emptying can affect the absorption of some oral medicines (FDA, 2025).

It does not make a GLP-1 medicine a systems-level replacement for blood-pressure, cholesterol, diabetes, or other treatment. A qualified prescriber may adjust medicines when clinical results justify it, but no one should stop or reduce a prescription independently. Deprescribing is a supervised decision, not a promised benefit of the drug.

What Happens If Treatment Stops?

Obesity is a chronic, relapsing condition, and the effect of medication often diminishes when the medication is withdrawn. In the STEP 1 extension, participants regained roughly two-thirds of the weight they had lost within one year of stopping semaglutide and the trial’s lifestyle intervention; several cardiometabolic improvements also moved back towards baseline (Wilding et al., 2022).

Regain is not proof that someone failed, lacked discipline, or became ‘dependent’ in a moral sense. It shows that the biological effects of treatment do not necessarily continue once treatment ends. Before starting, ask whether the plan is long term, what would prompt a dose change, how progress will be reviewed, and what support will remain if treatment is paused or stopped.

Safety And Side Effects

Nausea, vomiting, diarrhoea, constipation, and abdominal discomfort are among the most common side effects. Less common but important risks and precautions include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal symptoms, worsening diabetic retinopathy in some people with type 2 diabetes, and aspiration risk around anaesthesia or deep sedation (FDA, 2025).

Semaglutide is contraindicated for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 under the US label. It is not recommended for weight management during pregnancy, and planned procedures, pregnancy plans, and every current medicine or supplement should be discussed with the prescriber. The applicable Indian product information should guide local use.

The practical safety rule is simple: use a licensed product from an authorised source, prescribed for you, with a clear titration and follow-up plan. CDSCO has specifically warned consumers about falsified GLP-1 products sold through unregulated outlets and social media (CDSCO, 2023).

Protecting Nutrition, Muscle, And Function

Substantial weight loss includes both fat and lean tissue. A 2025 systematic review of randomised trials found that lean mass accounted for roughly one quarter of total weight lost with GLP-1-based treatment on average, although methods, populations, and individual results varied (Kleibert et al., 2025). Lean mass is not identical to skeletal muscle or strength, but the finding is a reason to monitor function rather than focus on kilograms alone.

Food quality, adequate protein and micronutrient intake, and resistance exercise matter during weight loss, particularly when appetite is low or weight is changing quickly. In an Indian diet, that may mean planning realistic portions of dal, beans, curd, paneer, eggs, fish, chicken, soy, or other suitable protein sources rather than assuming a smaller appetite will automatically produce a balanced diet.

Sleep and regular movement support metabolic health, but they should not be marketed as ways to reproduce a prescription medicine or ‘boost GLP-1 naturally’ to a therapeutic level. They remain valuable because they support health, function, and treatment sustainability in their own right. WHO’s 2025 guidance similarly places GLP-1 therapy within comprehensive long-term care that includes diet, physical activity, and professional support (WHO, 2025).

What The Indian Context Changes

India’s metabolic risk cannot be read from body size alone. The nationally representative ICMR-INDIAB study estimated diabetes prevalence at 11.4%, generalised obesity at 28.6%, and abdominal obesity at 39.5%, with substantial variation between states and between urban and rural populations (Anjana et al., 2023). More recent ICMR-INDIAB analysis also found a large group with metabolic risk despite a BMI below 25 kg/m² (Anjana et al., 2025).

This makes two shortcuts equally unhelpful: treating every larger body as a medication candidate, or assuming a lower BMI rules out metabolic risk. Indian clinical decisions need context, including waist measurement, glucose and lipid markers, blood pressure, family history, existing disease, medicines, and the person’s treatment history.

Access to GLP-1 and dual-incretin medicines in India has expanded, but access is not the same as indication. A prescription should follow an assessment, not a trend, a social-media recommendation, or a product bought without a verifiable supply chain.

Questions To Ask Before Starting

1. What condition are we treating, and what outcome will define success?
2. Why this medicine and dose rather than another option?
3. Which side effects, contraindications, and interactions apply to me?
4. Do any diabetes medicines need closer glucose monitoring or adjustment?
5. How will nutrition, resistance exercise, muscle function, and symptoms be supported?
6. What is the follow-up schedule, and whom do I contact if side effects are difficult?
7. Is the plan long term? If treatment stops, how will regain and other clinical changes be managed?
8. What should I do before surgery, deep sedation, or a planned pregnancy?

The Bottom Line

GLP-1 medicines are meaningful treatments, not miracle molecules. They can improve glucose control, support substantial weight loss, and reduce major cardiovascular events in selected high-risk groups. They have not been shown to slow ageing or preserve cognition, and they should not be used as a reason to abandon other necessary care.

A good protocol begins with the indication, includes the medication review, protects nutrition and function, plans for side effects, and is honest about duration. That is a more useful standard than being reflexively for or against the drug.

Next Step

Take the questions above to a qualified clinician who can review your health history, medicines, and goals. Do not start, stop, or change a GLP-1 medicine without medical guidance.

Frequently Asked Questions